Nebraska will receive nearly $5 million from Abbott Laboratories to settle concerns that it improperly marketed its anti-seizure drug Depakote.

Nebraska Attorney General Jon Bruning says the state will receive a share of the $1.5 billion settlement Abbott agreed to.

Nebraska's Medicaid program will receive $3.7 million, and $1.2 million will go to the state's consumer settlement fund.

Depakote is an anti-seizure and mood-stabilizing drug that's prescribed for bipolar disorder. Abbott admitted marketing Depakote for unapproved uses including dementia and schizophrenia in violation of FDA rules.

The national settlement was announced Monday.